Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.
- DOI
- 10.1080/10428194.2026.2677040
- Published
- 2026 Aug
- Container
- Leukemia & lymphoma
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/10428194.2026.2677040,
title = {Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.},
author = {Xu Y and Guan A and Xu CY and Shen KN and Li J},
year = {2026},
journal = {Leukemia \& lymphoma},
doi = {10.1080/10428194.2026.2677040},
url = {https://doi.org/10.1080/10428194.2026.2677040}
}RIS
TY - JOUR TI - Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis. AU - Xu Y AU - Guan A AU - Xu CY AU - Shen KN AU - Li J PY - 2026 JO - Leukemia & lymphoma DO - 10.1080/10428194.2026.2677040 UR - https://doi.org/10.1080/10428194.2026.2677040 ER -
APA
Y, X., A, G., CY, X., KN, S., & J, L. (2026). Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2026.2677040
Source records
- pubmed · retrieved 2026-09-26T07:56:50.380Z
- europe-pmc · retrieved 2026-09-26T07:56:50.393Z